NCT06094946

Brief Summary

Those prospective parturients that express that they may want an epidural labour analgesia for their delivery will be informed about the possibility to choose between a pump driven epidural or midwife administered intermittent boluses.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 16, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 23, 2023

Completed
1.1 years until next milestone

Study Start

First participant enrolled

December 1, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2025

Completed
Last Updated

April 24, 2024

Status Verified

April 1, 2024

Enrollment Period

2 months

First QC Date

October 16, 2023

Last Update Submit

April 23, 2024

Conditions

Keywords

epidural analgesialabour epiduralpatient controlled epidural

Outcome Measures

Primary Outcomes (1)

  • Parturient satisfaction with analgesia

    Visual analog scale 0-100 mm (0=dissatisfied; 100=maximum satisfaction)

    During use of labour analgesia (up to 6 hours)

Secondary Outcomes (2)

  • Midwife satisfaction with epidural labour analgesia

    During use of labour analgesia (up to 6 hours)

  • Support person's satisfaction with epidural labour analgesia

    During use of labour analgesia (up to 6 hours)

Study Arms (2)

Midwife administered boluses

The epidural analgesia is initiated by a manual bolus of the epidural solution (ropivacaine 1 mg/ml fentanyl 2.5 mug/ml) 10 + 10 ml and then continued on-demand by similar boluses until delivery

Drug: Ropivacaine HydroclorideDrug: Fentanyl Citrate

Automated and parturient controlled epidural boluses

The epidural analgesia is initiated by a manual bolus of the epidural solution (ropivacaine 1 mg/ml fentanyl 2.5 mug/ml) 10 + 10 ml and then continued by automated boluses of the same solution (6ml every 40 minutes) with possibility for the parturient to administer 6 ml extra doses with a 20 minute lock-out. Maximum hourly dose 20 ml.

Drug: Ropivacaine HydroclorideDrug: Fentanyl Citrate

Interventions

1 mg/ml

Automated and parturient controlled epidural bolusesMidwife administered boluses

2.5 micrograms/ml

Automated and parturient controlled epidural bolusesMidwife administered boluses

Eligibility Criteria

Age18 Years - 55 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Parturients coming to the delivery hospital (a tertiary delivery hospital with 8000 deliveries per year and 85 % epidural rate) for intended vaginal delivery and requesting epidural analgesia

You may qualify if:

  • Age 18 years or older
  • Admitted to the delivery hospital with the prospect of vaginal delivery
  • On admission when questioned about planned analgesia expresses that may want an epidural analgesia for the planned vaginal delivery
  • After reading the study prochure signs the participation (consent) form
  • Sufficient command of Finnish or Swedish to facilitate interview

You may not qualify if:

  • Contraindications for epidural analgesia
  • Planned cesarean delivery
  • Age under 18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

HUS/Women's hospital dept of anaesthesia

Helsinki, 00029, Finland

Location

MeSH Terms

Conditions

Labor Pain

Interventions

Fentanyl

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Riina Jernman, MD PhD

    Helsinki University Hospital Women's hospital

    STUDY DIRECTOR

Central Study Contacts

Antti J Vaananen, MD PhD

CONTACT

Riina Jernman, MD PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Anesthesiologist MD PhD

Study Record Dates

First Submitted

October 16, 2023

First Posted

October 23, 2023

Study Start

December 1, 2024

Primary Completion

February 1, 2025

Study Completion

February 1, 2025

Last Updated

April 24, 2024

Record last verified: 2024-04

Locations